Has Manzar Kuraishi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $716 in general payments to Manzar Kuraishi, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Manzar Kuraishi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Manzar Kuraishi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Manzar Kuraishi, MD

General Practice · Burbank, CANPI 1427028349

Payments from drug & device makers

$716in general payments, 2019–2025

Across 16 payments — averaging $44.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$481
Nevro Corp.$100
Medtronic$100
Johnson & Johnson$23
Lilly USA, LLC$12

What the payments were for

Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	11	$481
Nevro Corp.	1	$100
Medtronic	2	$100
Johnson & Johnson	1	$23
Lilly USA, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VRAYLAR$125
UBRELVY$122
Omnia$100

How this compares

$716 in reported general payments places this provider in the 75th percentile of 12,963 general practice providers in California.

See all general practice providers in California →

Medicare billing

Part B allowed, 2024

$158,105

Medicare patients

286

Services billed

1,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JanuviaSitagliptin Phosphate	19	$26,936
EliquisApixaban	12	$8,914
PremarinEstrogens, Conjugated	14	$6,984
TrintellixVortioxetine Hydrobromide	11	$5,375
SynthroidLevothyroxine Sodium	59	$4,393
Memantine Hcl	53	$2,579
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	17	$2,090
Nano 2nd Gen Pen NeedlePen Needle, Diabetic	19	$1,846
Metoprolol Succinate	115	$1,839
Levothyroxine Sodium	163	$1,800
TirosintLevothyroxine Sodium	12	$1,636
Losartan Potassium	143	$1,565
Amlodipine Besylate	184	$1,383
Finasteride	94	$1,319
Tamsulosin Hcl	87	$1,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieSynthroid	$481	$4,39359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 12,963 general practice providers in California.

Other general practice in Burbank

Hessam AazamiCanoga Park$88.4M
Frederic MollRedwood City$5.7M
Nathan LiLancaster$5.2M
Milton McCollSan Jose$4.9M
Bruce TorkanLos Angeles$3.8M
Daniel JohnsonPalm Desert$1.5M
Bradley ChingUpland$1.4M
Jared AdamsSan Francisco$862K
Marina GoldGlendale$784K
Eric BrassTorrance$755K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →